Challenges in the diagnosis and treatment of pulmonary arterial hypertension

European Respiratory Review

Volumn 21, Issue 126, 2012, Pages 313-320

  Vachiéry, Jean Luc ^a   Gaine, Sean ^b  

^a ERASME HOSPITAL   (Belgium)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Combination therapy; Diagnostic algorithms; Pulmonary arterial hypertensionspecific therapy; Screening

Indexed keywords

AMBRISENTAN; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; IMATINIB; MACITENTAN; PLACEBO; PROSTACYCLIN; SILDENAFIL; TADALAFIL; TREPROSTINIL;

BLALOCK HANLON OPERATION; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CLINICAL CLASSIFICATION; COMBINATION CHEMOTHERAPY; DELAYED DIAGNOSIS; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EXERCISE TEST; HEART CATHETERIZATION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART SURGERY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LUNG FUNCTION TEST; LUNG TRANSPLANTATION; MONOTHERAPY; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; SURVIVAL RATE; THORAX RADIOGRAPHY;

ALGORITHMS; ANTIHYPERTENSIVE AGENTS; CARDIAC CATHETERIZATION; DELAYED DIAGNOSIS; ELECTROCARDIOGRAPHY; EXERCISE TEST; HEART ATRIA; HUMANS; HYPERTENSION, PULMONARY; RADIOGRAPHY, THORACIC; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; VASODILATOR AGENTS;

EID: 84870765606     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00005412     Document Type: Review

References (45)

1. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 1998; 352: 719-725.
2. Galie' N, HoeperMM, HumbertM, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Respir J 2009; 34: 1219-1263.
3. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-163.
4. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue diseaseassociated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179: 151-157.
5. Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry. Chest 2012; 142: 448-456.
6. Ghofrani HA, Wilkins MW, Rich S. Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension. Circulation 2008; 118: 1195-1201.
7. Frost AE, Badesch DB, Barst RJ, et al. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest 2011; 139: 128-137.
8. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216-223.
9. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
10. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010; 137: 376-387.
11. Brown LM, Chen H, Halpern S, et al. Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. Chest 2011; 140: 19-26.
12. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: Suppl. 12, 40S-47S.
13. Farber HW, Foreman AJ, Miller DP, et al. REVEAL registry: correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension. Congest Heart Fail 2011; 17: 56-64.
14. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52: 3792-3800.
15. Baumgartner H, Bonhoeffer P, DeGroot N, et al. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J 2010; 31: 2915-2957.
16. Benza R, Biederman R, Murali S, et al. Role of cardiac magnetic resonance imaging in the management of patients with pulmonary arterial hypertension. J Am Coll Cardiol 2008; 52: 1683-1692.
17. McLure LE, Peacock AJ. Cardiac magnetic resonance imaging for the assessment of the heart and pulmonary circulation in pulmonary hypertension. Eur Respir J 2009; 33: 1454-1466.
18. Hoeper MM, Lee SH, Voswinckel R, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006; 48: 2546-2552.
19. Halpern SD, Taichman DB. Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. Chest 2009; 136: 37-43.
20. Lam CS, Roger VL, Rodeheffer RJ, et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a communitybased study. J Am Coll Cardiol 2009; 53: 1119-1126.
21. Jankowich MD, Rounds SI. Combined pulmonary fibrosis and emphysema syndrome: a review. Chest 2012; 141: 222-231.
22. National Health Service Information Centre. National audit of pulmonary hypertension 2011. www.ic.nhs.uk/services/nationalclinical-audit-support-programme-ncasp/audit-reports/heart-disease Date last accessed: June 12, 2012.
23. Galie' N, Rubin LJ, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093-2100.
24. Kawut SM, Taichman DB, Archer-Chicko CL, et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003; 123: 344-350.
25. Clements PJ, Tan M, McLaughlin VV, et al. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. Ann Rheum Dis 2012; 71: 249-252.
26. Sitbon O, Galie' N. Treat-to-target strategies in pulmonary arterial hypertension: the importance of using multiple goals. Eur Respir Rev 2010; 19: 272-278.
27. Hoeper M, Markevych I, Spiekerkoetter E, et al. Goal-orientated treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005; 26: 858-863.
28. Vachiéry JL, Yerly P, Huez S. How to detect disease progression in pulmonary arterial hypertension. Eur Respir Rev 2012; 21: 40-47.
29. Nickel N, Golpon H, Greer M, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2012; 39: 589-596.
30. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24: 353-359.
31. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174: 1257-1263.
32. Hoeper MM, Faulenbach C, Golpon H, et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004; 24: 1007-1010.
33. Simonneau G, Rubin LJ, Galie' N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008; 149: 521-530.
34. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010; 55: 1915-1922.
35. Tapson V, Torres F, Kermeen F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (The FREEDOM-C Study): a randomized controlled trial. Chest 2012; [Epub ahead of print DOI: 10.1378/chest.11-2212].
36. Hoeper M, Barst R, Bourge R, et al. Imatinib improves exercise capacity and hemodynamics at 24 weeks as add-on therapy in symptomatic pulmonary arterial hypertension patients: the IMPRES Study. Chest 2011; 140: 1045A.
37. Galie' N, Brundage B, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894-2903.
38. Peacock A, Keogh A, Humbert M. Endpoints in pulmonary arterial hypertension: the role of clinical worsening. Curr Opin Pulm Med 2010; 16: Suppl. 1, S1-S9.
39. Rubin L, Simonneau G. Perspective on the optimal endpoints for pulmonary arterial hypertension trials. Curr Opin Pulm Med 2010; 16: Suppl. 1, S43-S46.
40. Delcroix M, Spaas K, Quarck R. Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy. Eur Respir Rev 2009; 18: 253-259.
41. Lordan JL, Corris PA. Pulmonary arterial hypertension and lung transplantation. Expert Rev Respir Med 2011; 5: 441-454.
42. Vachiéry JL. Atrial septostomy. In: Humbert M, Souza R, Simonneau G, eds. Pulmonary Vascular Disorders. Volume 41. Basel, Karger, 2012; pp. 1-8.
43. Lammers AE, Haworth SG, Diller GP. Atrial septostomy in patients with pulmonary hypertension: should it be recommended? Expert Rev Respir Med 2011; 5: 363-376.
44. Keogh AM, Mayer E, Benza RL, et al. Interventional and surgical modalities of treatment in pulmonary hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S67-S77.
45. Sandoval J, Gaspar J, Peña H, et al. Effect of atrial septostomy on the survival of patients with severe pulmonary arterial hypertension. Eur Respir J 2011; 38: 1343-1348.